﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Journal of Cardiovascular and Thoracic Research</JournalTitle>
      <Issn>2008-5117</Issn>
      <Volume>9</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2017</Year>
        <Month>12</Month>
        <DAY>26</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Accelerated versus standard Streptokinase infusion regimen</ArticleTitle>
    <FirstPage>209</FirstPage>
    <LastPage>214</LastPage>
    <ELocationID EIdType="doi">10.15171/jcvtr.2017.36</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Ahmed</FirstName>
        <LastName>Bendary</LastName>
      </Author>
      <Author>
        <FirstName>Wael</FirstName>
        <LastName>Tawfik</LastName>
      </Author>
      <Author>
        <FirstName>Mohamed</FirstName>
        <LastName>Mahrous</LastName>
      </Author>
      <Author>
        <FirstName>Mohamed</FirstName>
        <LastName>Salem</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.15171/jcvtr.2017.36</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2017</Year>
        <Month>07</Month>
        <Day>30</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2017</Year>
        <Month>12</Month>
        <Day>24</Day>
      </PubDate>
    </History>
    <Abstract>Introduction: Timely fibrinolysis for acute ST-segment elevation myocardial infarction (STEMI) reduces infarct size and hence preserves LV function and reduces mortality. Optimal regimen of streptokinase (SK) infusion in such patients is a matter of interest. The current study aimed to compare efficacy and safety of accelerated SK infusion regimen in patients with STEMI versus the standard one.  Methods: One hundred consecutive STEMI patients were randomly allocated into one of 2 groups: group I (50 patients) who received accelerated SK regimen (1.5 million units over 30 minutes) and group II (50 patients) received standard SK regimen (1.5 million units over 60 minutes). Efficacy was evaluated non-invasively using clinical (chest pain), ECG (resolution of ST segment) and laboratory tests (earlier and higher peaking of cardiac troponin I). Safety was evaluated by assessment of multiple in-hospital adverse events.  Results: Both groups were statistically matched in all baseline criteria. There was a significant difference between both groups regarding each parameter of successful reperfusion in favor of accelerated regimen. When all these parameters were combined, 31 patients (62%) had successful reperfusion in group I versus 19 patients (38%) in group II (P = 0.016). We did not report any significant difference between both groups regarding in-hospital mortality, in-hospital heart failure, major bleeding, hypotension or allergic reaction to SK. Mean pre-discharge ejection fraction was higher in group I than group II (50.9 ± 6.6% versus 47.3 ± 4.6%, P = 0.002).  Conclusion: Accelerated regimen of SK infusion is safe and effective method of reperfusion in patients with STEMI.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Myocardial infarction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Streptokinase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Reperfusion</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>